doi: 10.1148/radiol.2017170102.
Epub 2017 Jul 21.
Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease
Affiliations
- PMID: 28731375
- DOI: 10.1148/radiol.2017170102
Item in Clipboard
Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease
Radiology.
2018 Jan.
Retraction in
-
Notice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal Disease.Radiology. 2018 Jan;286(1):120-121. doi: 10.1148/radiol.2017172255. Radiology. 2018. PMID: 29261455
Abstract
The authors have requested to withdraw this manuscript from publication because the study was not conducted in full accordance with the relevant institutional IRB protocol. © RSNA, 2018.
Similar articles
-
Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?Radiology. 2015 Sep;276(3):741-7. doi: 10.1148/radiol.2015142423. Epub 2015 Apr 15. Radiology. 2015. PMID: 25875973
-
Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.AJR Am J Roentgenol. 2015 Sep;205(3):469-78. doi: 10.2214/AJR.14.14268. AJR Am J Roentgenol. 2015. PMID: 26295633
-
Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.Clin Radiol. 2009 Jul;64(7):706-13. doi: 10.1016/j.crad.2009.04.004. Epub 2009 May 26. Clin Radiol. 2009. PMID: 19520215
-
Gadolinium-Induced Fibrosis.Annu Rev Med. 2016;67:273-91. doi: 10.1146/annurev-med-063014-124936. Annu Rev Med. 2016. PMID: 26768242 Review.
-
Nephrogenic systemic fibrosis: clinical spectrum of disease.J Magn Reson Imaging. 2009 Dec;30(6):1289-97. doi: 10.1002/jmri.21975. J Magn Reson Imaging. 2009. PMID: 19937929 Review.
Cited by
-
Gadolinium-based contrast agents: why nephrologists need to be concerned.Curr Opin Nephrol Hypertens. 2019 Mar;28(2):154-162. doi: 10.1097/MNH.0000000000000475. Curr Opin Nephrol Hypertens. 2019. PMID: 30531473 Free PMC article. Review.
-
Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018 Jun 12;5:2054358118778573. doi: 10.1177/2054358118778573. eCollection 2018. Can J Kidney Health Dis. 2018. PMID: 29977584 Free PMC article.
-
Clinical application and technical considerations of T1 & T2(*) mapping in cardiac, liver, and renal imaging.Br J Radiol. 2018 Dec;91(1092):20170825. doi: 10.1259/bjr.20170825. Epub 2018 Jul 23. Br J Radiol. 2018. PMID: 29975154 Free PMC article. Review.
-
10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.Invest Radiol. 2018 Sep;53(9):541-550. doi: 10.1097/RLI.0000000000000462. Invest Radiol. 2018. PMID: 29547493 Free PMC article.
-
Development of High Signal Intensity within the Globus Pallidus and Dentate Nucleus following Multiple Administrations of Gadobenate Dimeglumine.AJNR Am J Neuroradiol. 2018 Mar;39(3):415-420. doi: 10.3174/ajnr.A5510. Epub 2018 Jan 18. AJNR Am J Neuroradiol. 2018. PMID: 29348135 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
